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A Novel H2S-releasing Amino-
Bisphosphonate which combines 
bone anti-catabolic and anabolic 
functions
Simona Rapposelli  1, Laura Gambari2, Maria Digiacomo1, Valentina Citi1, Gina Lisignoli3, 
Cristina Manferdini3, Vincenzo Calderone1 & Francesco Grassi2
Bisphosphonates (BPs) are the first-line treatment of bone loss resulting from various pathological 
conditions. Due to their high affinity to bone they have been used to develop conjugates with pro-
anabolic or anti-catabolic drugs. We recently demontrated that hydrogen sulfide (H2S), promotes 
osteogenesis and inhibits osteoclast differentiation. Here we developed an innovative molecule, 
named DM-22, obtained from the combination of alendronate (AL) and the H2S-releasing moiety aryl-
isothiocyanate. DM-22 and AL were assayed in vitro in the concentration range 1-33 μM for effects 
on viability and function of human osteoclasts (h-OCs) and mesenchymal stromal cells (h-MSCs) 
undergoing osteogenic differentiation. Amperometric measures revealed that DM-22 releases H2S at 
a slow rate with a thiol-dependent mechanism. DM-22 significantly inhibited h-OCs differentiation 
and function, maintaining a residual h-OCs viability even at the high dose of 33 μM. Contrary to AL, 
in h-MSCs DM-22 did not induce cytotoxicity as revealed by LDH assay, significantly stimulated 
mineralization as measured by Alizarin Red staining and increased mRNA expression of Collagen I 
as compared to control cultures. In conclusion, DM-22 is a new BP which inhibits h-OCs function and 
stimulate osteogenic differentiation of h-MSCs, without cytotoxicity. DM-22 is an ideal candidate for a 
novel family of osteoanabolic drugs.
A progressive decline in bone strength is a common consequence of aging and several bone-wasting diseases in 
humans. Osteoporosis, the most prevalent cause of bone fragility, affects 1 in 2 women and 1 in 5 men age 50 and 
above and causes up to 9 million fractures per year worldwide1,2. Among pharmacological therapies, bisphospho-
nates (BPs) are the first-line and the most prescribed treatment for a number of diseases leading to abnormal bone 
turnover, including osteoporosis1. Key to the mechanism of action of BPs is the high affinity of these molecules for 
the mineralized bone matrix, which arises from the P-C-P backbone structure3,4. Once BPs bind hydroxyapatite 
within the bone matrix, the acidic pH caused by osteoclasts (OCs) resorption induces their dissociation from the 
mineral surface and the subsequent internalization within the OCs5. Owing to their strong affinity for the bony 
mineralized matrix, BPs have been broadly developed both as a powerful drugs for bone metabolism and as a 
carrier to achieve a targeted delivery of bone active molecules6,7. Among BPs, amino BPs (N-BPs) were found 
to be far more potent than simple BPs at inhibiting bone resorption8. N-BPs inhibit the mevalonate pathway by 
targeting the farnesyl diphosphate synthase (FPPS)9, leading to the accumulation of unprenilated GTPases in the 
cytoplasm, which results in toxicity and cell death9,10.
Clinical studies have conclusively showed that long-term use (up to 10 years) of BPs is associated to a good 
safety profile and to a significant reduction in the risk of vertebral, non-vertebral and hip fractures11,12. However, 
several studies have associated BPs therapy with a potential risk of osteonecrosis of the jaw13,14 and atypical sub-
trochanteric femoral fractures; at the cellular level, prolonged exposure to BPs was shown to eventually cause the 
suppression of osteoblast function both by direct and OC-mediated mechanisms15. The inability to restore the lost 
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bone structure may be the cause of poor bone quality and increased risk of atypical bone fractures in BPs treated 
patients16. Although the prevalence of side effect from BPs is very low, the impact from media reports has led to 
a dramatic decrease in the compliance to BPs therapies; for example, the use of alendronate (AL) has declined by 
over 50% from 2008 to 201217. As a consequence, drugs capable of stimulating bone formation while maintaining 
anti-resorptive activity can provide strong advantages as compared to current BPs.
A growing body of evidence indicates that hydrogen sulfide (H2S) is a gaseous molecule produced in substan-
tial amounts by mammalian tissues, which exerts a variety of physiological effects in different systems, including 
bone18. Consistently, the discovery of suitable H2S-donor agents and H2S-releasing multi-target drugs is currently 
considered a timely and challenging field of research in drug discovery19.
In particular, our group and others recently described that H2S inhibits h-OCs development in vitro20 and 
stimulates osteogenic differentiation of human mesenchymal stromal cells (h-MSCs) in vitro and in vivo18,21. 
Based on the dual action exerted by H2S, we sought to exploit these findings through the development of an 
H2S-releasing BPs, prototype of a novel family of hybrid molecules aiming at treating bone loss, by means of a 
multi-target pharmacological approach. An H2S-releasing BPs could allow a local delivery of H2S at the site where 
new bone formation is required thereby maximizing the osteogenic properties of H2S.
Ideal H2S-releasing moieties should generate H2S with a relatively slow rate; moreover, they should be stable, 
allowing an easy chemical manipulation22. In this perspective, we have recently investigated several organic sulfur 
compounds of either synthetic or natural origin23,24 and identified aryl-isothiocyanate as a suitable moiety, useful 
for building H2S-releasing hybrid drugs25.
This paper describes an innovative molecule, named DM-22, derived from the widely known N-BPs, AL, 
hybridized with an aryl-isothiocyanate - based H2S-releasing moiety. We investigated in vitro the potential bene-
ficial effects on bone cells of DM-22 compared to that of the parent drug AL.
Methods
Chemical synthesis. Melting points were determined on a Kofler apparatus and are uncorrected. Chemical 
shifts (δ) are reported in parts per million and are calibrated using residual undeuterated solvent as an internal 
reference. 1H NMR,31P NMR and13C NMR spectra of all compounds were recorded with a Varian Gemini 200 
spectrometer operating at 200 MHz or Bruker TopSpin 3.2 spectrometer operating at 400 MHz, in a ~2% solution 
of deuterated water (D2O), unless otherwise stated. Data for1H NMR spectra are reported as follows: chemical 
shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities are reported as follows: s = sin-
glet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, or combinations thereof. The 95% purity of 
tested compounds was confirmed by combustion analysis. ESI-MS/MS experiment was performed in negative ion 
mode, using a LCQ Advantage ion trap mass spectrometer (ThermoFinnigan, San Jose, CA, USA) equipped with 
Xcalibur 3.1 software. Merck gel plates (60 F254) were used for analytical TLC. UV light was used to examine the 
spots. Evaporation was performed in vacuo (rotating evaporator). Sodium sulfate was used as the drying agent. 
Commercially available chemicals were purchased from Sigma-Aldrich and TCI Chemicals. The synthesis of 
DM-22 was performed in 3 steps characterized by the preparation of the following intermediate products.
4-(4-nitrobenzamido)butanoic acid (1). p-nitrobenzoic acid (300 mg, 1.64 mmol) was treated with thio-
nyl chloride (685 mg, 5.76 mmol) at 80 °C for 12 h. The solvent was evaporated to yield a yellow solid which was 
dissolved in a small amount of THF and added dropwise to a solution of γ-aminobutyric acid (78 mg, 0.76 mmol) 
in aqueous NaOH (156 mg, 4.40 mL). The resulting solution was stirred at room temperature (RT) for 12 h; Then, 
the pH value was adjusted to 2 by the addition of HCl 1 N. The precipitate was collected and crystallized from 
H2O thus yielding a white solid corresponding to the product (1) (197 mg, yield 74%): 1H-NMR (CD3OD): δ 
1.86–2.00 (m, 2 H, CH2); 2.41 (t, 2 H, J = 7.3 Hz, CH2); 3.46 (t, 2 H, J = 6.9 Hz, CH2), 8.02 (d, 2 H, J = 9.0 Hz, Ar); 
8.32 (d, 2 H, J = 9.0 Hz, Ar) ppm.
4-(4-aminobenzamido)butanoic acid (2). To a solution of 4-(4-nitrobenzamido)butanoic acid (77 mg, 
0.31 mmol) in MeOH (2 mL) was added carbon (16 mg), a catalytic amount of FeCl3 and hydrazine monohy-
drate (116 mg, 5.18 mmol). The resulting mixture was refluxed for 24 h. Afterwards, the reaction mixture passed 
through a pad of celite and the solvent evaporated affording a crude product that was purified by precipitation 
from EtOH/Et2O (43 mg, yield 64%).1H-NMR (CD3OD): δ 1.80–1.94 (m, 2 H, CH2); 2.28 (t, 2 H, J = 7.2 Hz, CH2); 
3.37 (t, 2 H, J = 6.8 Hz, CH2), 6.66 (d, 2 H, J = 8.5 Hz, Ar); 7.60 (d, 2 H, J = 8.5 Hz, Ar) ppm.
(1-hydroxy-4-(4-isothiocyanatobenzamido)butane-1,1-diyl)diphosphonic acid (DM-22). A 
solution of cathecol borane in THF 1 M (0.88 mL, 0.88 mmol) was added to compound 2 (63 mg; 0.28 mmol) 
under N2 atmosphere. The reaction mixture was stirred at RT for 1 h. Then, P(OSiMe3)3 (347 mg, 1.16 mmol) was 
added to the reaction mixture and stirred at rt for 16 h. The solvent was removed in vacuo to give a crude residue, 
which was triturated with CHCl3. The crude oil was dissolved in a solution of NaHCO3 0.4 M (2 mL) and thio-
phosgene (228 mg, 1.98 mmol) was added to the reaction mixture and stirred at RT for 2 h. Finally, the reaction 
mixture was extracted with dichloromethane (DCM). The combined organic layers were dried over MgSO4, and 
filtered, and the solvent was removed in vacuo to give a residue, which was triturated with hexane to obtain the 
final product (20 mg, yield 24%).1H-NMR (D2O): δ 1.90–2.15 (m, 4 H, CH2); 3.45 (t, 2 H, J = 6.6 Hz, CH2); 7.43 (d, 
2 H, J = 8.8 Hz, Ar), 7.80 (d, 2 H, J = 8.8 Hz, Ar) ppm.13C-NMR (D2O): δ 167.70, 129.37, 128.93, 126.39, 124.06, 
123.70, 76.66, 40.56, 31.24, 23.52 ppm.31P- NMR (D2O) δ 19.23 ppm; ESI-MS m/z calculated for C12H16N2O8P2S, 
410.01; found, 409.45. [M - H+].
Determination of H2S release by amperometric assay. The characterization of the potential 
H2S-generating properties of DM-22 has been carried out by an amperometric approach, through the Apollo-4000 
free radical analyzer (WPI) detector and H2S-selective mini-electrodes. 6 different recordings have been carried 
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out at RT. Following the manufacturer’s instructions, a “PBS buffer 10x” was prepared (NaH2PO4•H2O 1.28 g, 
Na2HPO4.12H2O 5.97 g, NaCl 43.88 g in 500 ml H2O) and stocked at 4 °C. Immediately before the experiments, 
the “PBS buffer 10x” was diluted using distilled water (1:10) to obtain the assay buffer and the pH adjusted to 
7.4. The H2S-selective mini-electrode was equilibrated in 10 ml of the assay buffer, until the recovery of a stable 
baseline. Then, 100 μl of a dimethyl sulfoxide (DMSO) solution of DM-22 was added (the final concentration 
of DM-22 was 1 mM; the final concentration of DMSO in the assay buffer was 1%). The generation of H2S was 
observed for 20 min. Preliminary experiments demonstrated that DMSO 1% did not produce any interference 
on the amperometric recording. When required by the experimental protocol, L-Cysteine (final concentration 
4 mM) was added 10 min before the addition of DM-22. L-Cysteine alone did not produce any amperometric 
response. The correct relationship between the amperometric currents (recorded in pA) and the corresponding 
concentrations of H2S was previously determined by suitable calibration curves, which were obtained by the use 
of sodium hydrosulfide, an H2S donor, (NaHS; 1-3-5-10 μM) at pH 4.0.
h-monocytes (CD11b+ cells) isolation. In preparing samples for human tissues, all protocol and pro-
cedures were in accordance with the ethical standards of the institutional ethical committee of the Rizzoli 
Orthopedic Institute, who approved the study, and with the 1964 Helsinki Declaration and its later amendments.
Human monocytes (h-monocytes) were isolated from peripheral blood mononuclear cells (PBMCs) of 3 
healthy donors, carrying out a gradient separation with Ficoll (Lympholite-H, Cederlane, Burlington, Ontario, 
Canada) followed by immunomagnetic positive selection of CD11b+ cells (MACS system, Miltenyi Biotech, 
Calderara di Reno, Italy), according to procedures well established in our laboratory26. Purity of CD11b+ 
enriched population was assayed by flow cytometry (FACS) analysis using FACS canto II (BD bioscience, San 
Jose, California, USA).
h-OCs differentiation. h-monocytes were seeded in quadruplicate into 96 well-plates at a density of 5 × 105 
cells/cm2. h-OCs were obtained by culturing h-monocytes for 6 days α–MEM medium (Euroclone, Milan, Italy) 
supplemented with 10% FBS (Lonza, Basel, Switzerland) and 1% penicillin/streptomycin, in the presence of 
M-CSF (10 ng/ml) and RANKL (75 ng/ml) (Miltenyi Biotech). Cells were cultured in presence or absence of AL 
and DM-22 (1, 3.3, 10, 33 µM); medium and stimuli were replaced three times per week.
Cytotoxicity and TRAP assay on OCs. h-monocytes were seeded as above and cultured in α–MEM 5% 
FBS (Thermo Fischer Scientific, Waltham, Massachusetts, U.S.A) depleted of phenol-red for 24–72 h in the pres-
ence or absence of increasing concentrations of AL and DM-22 (1-3.3-10-33 µM). Lactate dehydrogenase (LDH) 
assays (Cytotoxicity detection kit (LDH), Roche) were performed on supernatants, according to manufacturer 
instructions, to test the acute toxicity. Colorimetric detection of LDH was performed at 492–620 nm on TECAN 
instrument and cytoxicity calculated with reference to the control (unstimulated samples) and positive control 
(Triton X-100 treated samples) according to the formula: [(experimental value-unstimulated control value)/
(Positive control-unstimulated control value)]*100. According to the previous formula unstimulated control 
value express a 0% of cytotoxicity while positive control a 100% of cytotoxicity.
To evaluate OC differentiation, tartrate acid phosphatase (TRAP) assay (Acid Phosphatase, Leukocyte (TRAP) 
Kit, Sigma Aldrich) was performed after 7 days in culture. Mature h-OCs were defined as TRAP positive cells 
containing at least three nuclei and were manually counted using an inverted microscope; 8 microscope fields at 
20X magnification were counted for each duplicate well and the h-OCs count was expressed as average h-OCs 
number/fields.
Functional assay for mature h-OCs (pit assay). For pit assays, h-monocytes were seeded on synthetic 
hydroxyapatite-coated 16-well slides (Osteologic slides, BD Pharmingen, Franklin Lakes, NJ, USA), which mim-
ics in vitro bone matrix, at the density of 5 × 105/cm2.
h-OCs were obtained by culturing h-monocytes for 7 days in osteoclastogenic medium in presence or 
absence of AL and DM-22 (1–3.3–10–33 µM). After washing with bleach to eliminate cells, pits formed on the 
Osteologic slides upon matrix breakdown by h-OCs, were captured by NIS software (Nikon, Firenze, Italy) and 
Nikon Instruments Europe BV (Amstelveen, the Netherlands) using differential interference contrast system and 
evaluated.
h-MSCs isolation and culture. Bone resident h-MSCs were isolated, after obtaining informed consent 
by each donor, from the tybial plateau of 6 patients undergoing surgical knee replacement according to pro-
cedure well established by our laboratory27. Briefly, bone fragments were mechanically fragmented into small 
pieces to generate a cell suspension which was subjected to Ficoll-density gradient isolation protocol as previously 
reported27. Cells were grown and expanded in α–MEM medium supplemented with 15% FBS and 1% penicillin/
streptomycin until passage 2.
Cytotoxicity assay on hMSCs. h-MSCs were seeded into 96 well-plates at a concentration of 3 × 104 cells/ 
cm2 in α–MEM 7,5% FBS depleted of phenol-red for 24–72 h in the presence or absence of increasing concentra-
tions of AL and DM-22 (1–3.3–10–33 µM). Morphological analysis was examined under light microscope. Photos 
were taken using Nikon Instruments after having performed toluidine blue assay for increasing the sharpness of 
cells. Cells were fixed in formalin 10% for 20 min, toluidine was added for few seconds and then cells were washed 
with deionized water to eliminate unspecific staining. Afterwards, the positive staining was measured at 560 nm 
on TECAN Infinite® 200 PRO (Tecan Italia S.r.l., Cernusco Sul Naviglio, Italy). LDH assays (Cytotoxicity detec-
tion kit (LDH), Roche) were performed as described above.
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h-MSCs proliferation. h-MSCs were seeded in quadruplicates in 96-well plates at 3 × 104 cells/cm2 and 
cultured in α-MEM 15% FBS at 37 °C, 5% CO2 and 95% O2. Proliferation was tested after 24 and 72 h in culture. 
18 h before each time point, 5 µCi of3H-thymidine (Perkin Elmer, Boston, MA, USA) was added to each well and 
radioactivity was then measured using a beta-counter (Perkin Elmer).
h-MSCs osteogenic differentiation. Cells were harvested and seeded into 12 well-plates at a concentra-
tion of 5 × 104 hMSCs/cm2. Cells were induced toward osteogenic differentiation with α-MEM 20% FBS supple-
mented with 0,1 µM dexamethasone (Sigma Aldrich, St. Louis, MO, USA), 100 µM ascorbic acid (Sigma Aldrich) 
and 10 mM β-glicerolphosphate (Sigma Aldrich) in the presence or absence of AL and DM-22 (1–3.3–10–33 µM). 
Cells were cultured for up to 21 days at 37 °C, 5% CO2 and 95% O2 and medium was replaced twice per week. 
Alizarin Red S (AR-S) staining (Sigma Aldrich) was performed as follows. Cells were fixed for 15 minutes at RT 
in formaldehyde (Kaltek, Padova, Italy) 10% phosphate buffered saline (PBS), washed twice with PBS, stained 
with 40 mM AR-S for 20 minutes at RT and washed with deionized water to eliminate unspecific staining. A 
spectrophotometric analysis with TECAN was used to quantify AR-S positive stain. Briefly, absorbance was red 
at 510 nm, as previously detailed27, and data were further elaborated subtracting the levels of background. As a 
result, readings which do not detect a positive stain gave negative values.
Reverse Transcription-Polymerase chain reaction (RT-PCR). To evaluate gene expression, RNA was 
isolated with RNApure (Euroclone), and purified from DNA with DNA-free™ Kit (Ambion, Life Technologies; 
Carlsbad, California, U.S.A) according to manufacturer instructions. RNA concentration was assessed by 
Nanodrop 2000c (Thermo Scientific, Rockford, IL, USA) and the quality of RNA was analyzed through the 
260/280 and 260/230 nm absorbance ratio. Only samples showing a 260/280 ratio >1.8 were used for the fol-
lowing transcription step. Reverse transcription (SuperScript® VILO™ cDNA Synthesis Kit; Invitrogen, Life 
Technologies) was performed utilizing 0,5-1 µg of RNA according to manufacturer instruction as follows: 25 °C 
for 10 minutes, 42 °C for 60 minutes, 85 °C for 5 minutes and 4 °C for 30 minutes on 2720 Thermal cycler (Applied 
Biosystem, Life Technologies). Polymerase chain reaction (PCR) (SYBR Premix Ex Taq, TaKaRa Biomedicals, 
Tokyo, Japan; LightCycler Instrument, Roche) was performed on 20 ng cDNA as following: one cycle at 95 °C for 
10 seconds and 45 cycles at 95 °C for 5 seconds and at 60 °C for 20 seconds. The specificity of the PCR products 
was confirmed by standard melting curve analysis with the following thermal cycling profile: 95 °C for 10 seconds, 
65 °C for 15 seconds and 95 °C in one-degree increments. Relative quantification of PCR products was obtained 
with the comparative CT method, comparing to the housekeeping mRNA expression of glyceraldehyde-3 phos-
phate dehydrogenase (GAPDH). All the primers, whom sequences are reported in Table 1, were obtained from 
Life Technologies.
Statistical analysis
GraphPad Prism 7 (La Jolla, CA, USA) and IBM SPSS Statistics (New York, USA) software were used for statistical 
analyses. D’Agostino-Pearson omnibus test was performed to test normality of continuous variables. Data on H2S 
release by DM-22 were analyzed by two-way ANOVA followed by Bonferroni post-test.
Multiple comparisons were made by one-way ANOVA and Tukey multiple comparison tests or Kruskall-Wallis 
and Dunn’s multiple comparison test, respectively in parametric or non-parametric data set. Simple comparisons 
were made by using Unpaired t-test or Mann-Whitney test, respectively in parametric or non-parametric data set. 
Wilcoxon signed rank test was used to compare each sample with a hypothetical value (1 or 100) for analysis of 
fold increase. A statistical multivariate analysis, the Generalized Linear Model (GLM), was used to analyze three 
groups of non-parametric data in the osteogenic gene expression data set.
P values < 0.05 were considered statistically significant.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
Extended name GENE symbol 5′-Sequence-3′ Product size (bp) Accession number
Glyceraldehyde-3 
phosphate dehydrogenase GAPDH
Forward CGGAGTCAACGGATTTGG
218 NM_002046
Reverse CCTGGAAGATGGTGATGG
Alkaline phosphatase ALP
Forward GGAAGACACTCTGACCGT
152 NM_000478
Reverse GCC CAT TGC CAT ACA GGA
Bone sialoprotein BSP
Forward CAGTAGTGACTCATCCGAAG
158 NM_004967
Reverse CATAGCCCAGTGTTGTAGCA
Collagen type I COLL I
Forward GAGAGCATGACCGATGG
251 NM_000088
Reverse GTGACGCTGTAGGTGAA
Collagen type XV COLL XV
Forward AAGCCGTCACCTACACTCAA
228 NM_001855
Reverse CACCATCCACAGAATGAACC
Table 1. Primers sequences utilized in the experiments.
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Results
Chemistry. The new hybrid compound was synthesised as reported in Fig. 1. Briefly, the condensation of 
p-nitrobenzoic acid with the γ-aminobutirric acid in an aqueos solution of NaOH yielded the amide 1 (Fig. 1a). 
The subsequent reduction of the nitro group with hydrazine monohydrate in the presence of FeCl3 gave the 
4-(4-aminobenzamido)butanoic acid 2 (Fig. 1b). The intermediate namely the 1-hydroxy-1,1,-bisphosphonic acid 
was obtained through an efficient and simple one-pot synthesis starting from the carboxylic acid 1, cathecol-bo-
rane and tris(triethylsylilphosphate)28. The final reaction with thiophosgene and NaHCO3 yielded the isothioci-
anate derivative DM-22 (Fig. 1c). The H2S donor-BP was characterized by 1H, 13C, 31P NMR spectra.
DM-22 is a slow-releasing H2S donor. The incubation of DM-22 1 mM in aqueous solution (assay buffer, 
at pH 7.4 and 20 °C), in the presence of L-Cysteine 4 mM, led to the generation of a time-related increasing 
concentration of H2S (Fig. 2). The rise of the H2S production reached a steady-state after about 10 min and the 
highest concentration of H2S, recorded after 20 min was 42.0 ± 2.1 µM. In contrast, in the absence of L-Cysteine, 
the incubation of DM-22 1 mM led to the formation of dramatically lower levels of H2S (1.8 ± 0.1 µM, after 20 min 
of incubation). Such a organic thiol-dependent mechanism of H2S release is in agreement with previous observa-
tions on aryl-isothiocyanates25, and even on different chemotypes of H2S-donors, such as thioamides23 or organic 
disulfides29.
DM-22 inhibits h-OCs differentiation and function without inducing cytotoxicity. Firstly we 
investigated the safety profile of DM-22 by analyzing its cytotoxicity on mature h-OCs by LDH assay. As shown 
in Fig. 3A, DM-22 displayed no cytotoxicity throughout the concentration range tested. Negative values of cyto-
toxicity are explained by the fact that DM-22 stimulation resulted in reading values below the baseline levels gen-
erated by control, unstimulated sample (=0). On the contrary, AL consistently revealed a detectable cytotoxicity, 
which was significantly higher than DM-22 at each concentration tested in our experiments (p < 0.05 for 1 and 
3.3 μM, p < 0.01 for 10 μM, p < 0.0001 for 33 μM versus DM-22, Fig. 3A).
Next, we asked whether DM-22 retained the AL-like inhibition on osteoclastogenesis. Analysis of osteoclasto-
genic differentiation revealed a different pattern of inhibition by DM-22 compared to AL. Representative pictures 
of TRAP + hOCs at the end of the culture period are shown in Fig. 3B. DM-22 significantly decreased the number 
of mature hOCs at all the concentrations tested (Fig. 3C; p < 0.05 for 1 μM, p < 0.01 for 3.3 and 10 μM, p < 0.0001 
for 33 μM vs control sample). Inhibition of h-OCs differentiation peaked at the high concentration of 33 μM, 
where no cytotoxicity had been shown, and reached nearly 40% inhibition relative to control samples.
Figure 1. Scheme of chemical synthesis of DM-22. Reagents and conditions: a) (i) SOCl2, 80 °C, 2 h (ii) 
γ-aminobutyrric acid, NaOH, 5 °C → RT 12 h; b) NH2NH2, FeCl3, C, MeOH, 24 h; c) (i) catecholborane 1 M, 
P(OSiMe3)3, 1 h (ii) thiophosgene, NaHCO3 0.4 M, 2 h.
Figure 2. Graph of H2S release from DM-22. The graph shows the progressive increase of the concentration 
of H2S, following the addition of DM-22 into an acqueous solution (pH 7.4) in the absence (squares) or in the 
presence (triangles) of an excess (4 mM) of L-Cysteine. Results are expressed as mean ± SEM of 6 different 
recordings.
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Figure 3. DM-22 inhibits h-OCs differentiation and function without inducing cytotoxicity and preserving 
a residual h-OCs population. (A) Histogram showing LDH measurements. Data are expressed as percent 
cytotoxicity and refers to arbitrary units obtained by colorimetric detection of LDH activity. Data are 
expressed as mean ± SD of triplicates of N = 3 independent experiments. One sample t-test was performed for 
statistical analyses (*p < 0.05, **p < 0.01, ***p < 0.001 DM-22 vs AL). (B) Representative pictures of TRAP 
staining (magnification 20X), showing the effect of DM-22 and AL on h-OCs differentiation. (C) Histograms 
showing the average number of TRAP+ h-OCs per microscope field. At least 8 fields were counted for each 
well in duplicate. Data are expressed as mean ± SD of N = 3 independent experiments. Mann-Whitney 
test (####p < 0.0001 DM-22 vs AL) or Wilcokon signed rank test (*p < 0.05, **p < 0.01, ****p < 0.0001 vs 
CTRL = 100%) were performed for statystical analyses. (D) Representative pictures of pit assay (magnification 
20X), showing the effect of DM-22 and AL on h-OCs function.
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As expected, AL dose-dependently decreased the total number of TRAP+ h-OCs, resulting into highly signifi-
cant inhibition at all the concentrations tested (p < 0.0001 vs control sample) (Fig. 3C). In particular AL decreased 
the number of h-OCs by 62% and 77%, respectively, at 1 and 3.3 μM and virtually abolished h-OCs differentiation 
starting from the concentration of 10 μM.
These data suggest that DM-22 likely preserve a residual population of h-OCs, important for the mantainment 
of bone turnover.
Coherently, the ability of mature h-OCs to break down a mineral substrate, as tested in vitro by the ‘pit assay’, 
was strongly prevented by 1 μM of AL treatments and virtually completely inhibited by higher concentrations 
(Fig. 3D). Conversely, h-OCs function was dose-dependently inhibited by DM-22.
DM-22 is devoid of AL-like cytotoxicity on h-MSCs. Next we investigated the effect of DM-22 on 
h-MSCs on viability and proliferation. Staining with the vital dye toluidine blue revealed that treatment with 
DM-22 and AL at the highest concentration (33 μM) triggered a different response on h-MSCs after 72 h in cul-
ture (Fig. 4A,B). While DM-22 did not alter the intensity of staining compared to control samples (Fig. 4A-a,c; 
Fig. 4B), AL induced a marked decreased in cellularity (Fig. 4A-a,d); moreover, after AL treatment, h-MSCs 
showed occasionally picnotic nuclei (Fig. 4A-d) and the intensity of staining was significantly decreased com-
pared to control samples, close to the value induced by treatment with the detergent Triton X-100 (CTRL+, 
Fig. 4B).
Next we investigated the acute cytotoxicity within a time-range of 72 h. Quantification of LDH assay per-
formed after 24 h (Fig. 4C) and 72 h (Fig. 4D) confirmed that DM-22 was completely devoid of cytoxicity at all 
the concentration tested. Consistant with data revealed by toluidine blu staining, the highest concentration of AL 
resulted in significant cytoxicity in h-MSCs after 72 h in culture (Fig. 4D; 20%; p < 0.0001). Significant cytotox-
icity was also induced by 10 μM AL, however the percentage of inhibition is negligible compared to that of the 
highest dose (Fig. 4D; 1%; p < 0.05).
Analysis of cell proliferation in h-MSCs also revealed that AL treatment induce a dose-dependent decrease 
in cellular proliferation, resulting into a significant inhibition at 33 μM at 72 h in culture (Fig. 4E,F). The highest 
concentration of AL induced a maximum inhibition of proliferation of nearly 50% relative to control samples 
after 72 h (p < 0.01). Although DM-22 also induced a significant inhibition of cell proliferation at the highest con-
centration (20%, p < 0.01), it showed a markedly lower inhibition of cell proliferation compared to AL (Fig. 4F; 
p < 0.05).
DM-22 stimulates mineralization and expression of osteogenic markers in h-MSCs. To further 
assess the effect of DM-22 on h-MSCs function, we investigated bone resident h-MSCs during in vitro osteo-
genic differentiation. Figure 5A shows representative pictures of AR-S staining at the day 21 time point for each 
treatment. As expected, control cultures of h-MSCs under osteogenic stimuli produce large mineralized nodules 
(Fig. 5A); interestingly, stimulation with DM-22 resulted in further increase of mineral matrix apposition, which 
induced a significant increase in mineralization as detected by quantification of nodules positive to AR-S stain-
ing at all the concentrations tested (Fig. 5B, p < 0.05, p < 0.001). A similar treatment with AL induced a marked 
inhibition of mineralization, which became evident by 1 μM and 3.3 μM (Fig. 5A), concentration levels that did 
not previously show cytoxicity (Fig. 4C,D). Consistant with findings showing rising cytoxicity of AL, stimulation 
with higher concentrations of AL resulted in the complete inhibition of mineral matrix deposition by h-MSCs 
(Fig. 5A,B; p < 0.01, p < 0.0001).
To further investigate the nature of DM-22 stimulation of osteogenic differentiation, we evaluated mRNA 
expression of osteogenic markers during the osteogenic culture (D14) and at the end of the experiment (D21).
Figure 6 summarizes gene expression of ALP (Fig. 6A,B), BSP (Fig. 6C,D), COLL I (Fig. 6E,F) and COLL 
XV (Fig. 6G,H). The GLM statistical analysis revealed that mRNA expression was affected by DM-22 or AL 
independent of the dose used; as a consequence, data are represented as box plots showing the overall effect of 
stimuli on the expression of target genes. h-MSCs stimulated with DM-22 showed significantly higher expression 
of COLLI at D14 in culture (Fig. 6E, p < 0.05) compared to control samples. DM-22 also induced gene expression 
above that of control samples for ALP at D14 (Fig. 6A), BSP at D21 (Fig. 6B), COLLXV at D21 (Fig. 6H); however, 
due to the high variability in response, these comparison did not achieve statistical significance in our analysis. 
When compared to AL-treated h-MSCs, DM-22 induced consistantly higher gene expression level for all the 
endpoints examined; in particular, mRNA of ALP D14 (Fig. 6A, p < 0.05), COLLI D14-D21 (Fig. 6E,F, p < 0.05) 
and COLLXV D14 (Fig. 6G, p < 0.05) was significanlty higher in samples treated with DM-22 compared to AL. 
Moreover, AL suppressed mRNA expression of ALP at D14-D21 (Fig. 6A,B, p < 0.05), COLLI at D21 (Fig. 6F, 
p < 0.05) and COLLXV D14 (Fig. 6G, p<0.05) compared to control h-MSCs. Notably, for the same genes at the 
same time point, DM-22 stimulation did not suppress mRNA expression levels compared to control samples.
Discussion
H2S has recently shown an unexpected role in bone biology as a pivotal regulator of bone turnover. In the present 
study, we exploited the properites of H2S into a novel H2S-releasing BPs, named DM-22, obtained by “chemical 
hybridization” of AL, the lead compound in the N-BPs class, with an aryl-isothiocyanate-based H2S-releasing 
moiety. We investigated the main pharmacodynamic features of DM-22 in vitro and assessed its efficacy and 
safety in h-MSCs and h-OCs.
Electrochemical measurements demonstrated that DM-22 released H2S with a long-lasting kinetic, in line 
with the feature of isothiocyanate-based H2S-donor23,24. In designing this hybrid drug, such a pharmacological 
property was expected to improve the whole pharmacological profile and to attenuate the possible cytotoxicity of 
the BPs molecular portion.
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DM-22 has been designed to meet the need for molecules showing improved efficacy and safety profile as 
compared to existing drugs for bone metabolism.
BPs are the first-line treatment for the therapy of several bone-wasting conditions30. However, long-term treat-
ments with BPs are associated with an increased risk of developing adverse events; for example, epidemiological 
Figure 4. DM-22 is devoid of AL-like cytotoxicity on h-MSCs. (A) Representative pictures of toluidin blue 
staining showing the morphology of AL or DM-22 treated h-MSCs (33 μM) compared to untreated cells (CTRL) 
and cells treated with Triton X-100 (CTRL+). Magnification 20x. (B) Histogram showing toluidin blue staining 
quantification (absorbance 560 nm). Data are expressed as mean ± SD of N = 3 independent experiments (each one 
in quadruplicate). One way Anova and Tukey’s multiple comparison test were performed for statistical analyses. 
(C,D) Histograms showing LDH measurements in h-MSCs treated with DM-22 or AL compared to CTRL 
cells at 24 h (C) and 72 h (D); data are expressed as percent cytotoxicity and refers to arbitrary units obtained by 
colorimetric detection of LDH activity. Data are expressed as mean ± SD of N = 3 independent experiments (each 
one in quadruplicate). Mann Whitney test was performed for statistical analyses (*p < 0.05, ****p < 0.0001 DM-22 
vs AL). (E,F) Histograms showing h-MSCs proliferation as revealed by 3H-thymidine detection for DM-22 and AL 
compared to CTRL cells at 24 h (E) and 72 h (F) Data are expressed as fold increase compared to CTRL sample and 
are expressed as mean ±SD of N = 4 independent experiments (each one in quadruplicate). Wilcoxon signed rank 
test (*p < 0.05, **p < 0.01) and Mann-Whitney test (#p = 0.0516) were performed for statistical analyses.
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studies have established a compelling association between BPs potency, duration of treatment and the risk for 
developing osteonecrosis of the jaw31 as well as atypical, low energy fractures32. Long-term therapy with AL 
has been recently associated with the accumulation of microcracks in bone leading to reduced bone strenght 
in patients33, consistant with the hypothesis that excessive suppression of bone turnover can deteriorate bone 
quality16. Moreover, a recent report from the multidisciplinary task force of the American Society for Bone and 
Mineral Research (ASBMR) highlighted that, although the benefits of BPs treatment by far outweighs the risk of 
incurring in side effects, over 50% of patients failed to adhere to treatment longer than 12 months due, at least in 
part, to concerns about side effects.
DM-22 did not show cytoxicity in h-OCs at any of the concentrations tested. However, DM-22 induced a 
significant reduction of the number of mature h-OCs at all concentrations, although the inhibition was more 
pronounced at the highest concentration of 33 μM. By contrast, AL triggered a much more pronounced inhibition 
of h-OCs differentiation which was accompanied by an increased cytoxicity; consistant with previous reports34,35, 
AL completely abolished h-OCs differentiation and their ability to resorb mineral matrix in the concentration 
range between 1 and 33 μM.
Although we did not investigate the mechanism for the reduced anti-resorptive activity of DM-22, it is con-
ceivable that the structural modification induced at the R2 side chain of AL is responsible for such a decreased 
activity. Indeed, it is known that increasing the distance between the nitrogen and the phosphonate group in 
N-BP results into a decreased ability to inhibit farnesyl diphosphate synthase (FPPS) in OCs36. Overall, DM-22 
showed a moderate ability to act as anti-resorptive agent and mitigated the effects of AL by preserving h-OCs 
viability even in the upper concentration range tested in our experiments.
At the cellular level, our findings support the hypothesis that AL directly inhibits osteogenic differentiation 
and cause cytotoxicity in osteoprogenitor cells. Whether AL stimulate or inhibits osteogenic differentiation of 
MSCs in vitro is a controversial matter in previous reports and appears to be dependent on the protocol used; our 
data correlate with similar findings obtained using h-MSCs37 and with work by Orriss et al. showing cytotoxic 
inhibition of osteoblast proliferation and function in rats by N-BPs in the low micromolar concentration range15. 
Moreover, in broad agreement with our observations, it was reported that AL inhibits bone nodule formation at 
concentrations 10-fold lower than those required to induce apoptosis in rabbit calvarian osteoblast38. By contrast, 
AL was shown to stimulate osteogenic differentiation of h-MSCs39 peaking at 10 nM, a concentration 100-fold 
lower than the low-dose used in our experiments. One possible explanation for these diverging effects could be 
that AL triggers an hormetic dose-response during osteogenic differentiation of h-MSCs.
Compared to its parent molecule, DM-22 showed a substantially improved profile of safety and efficacy on 
h-MSCs induced to osteogenic differentiation within the same concentration range. DM-22 was devoid of cyto-
toxicity even at the high dose of 33 μM; even though a slight decrease in cell proliferation was induced by DM-22 
at the high concentration of 33 μM, it did not affect cell viability and the ability of this compound to significantly 
increase the extent of mineralizing matrix as compared to control h-MSCs.
Semi-quantitative analysis of gene expression in h-MSCs provided further evidence of the potential osteo-
anabolic role of DM-22. h-MSCs stimulated with DM-22 showed consistantly higher mRNA expression than 
Figure 5. DM-22 increased mineralization in osteogenic h-MSCs. (A) Representative pictures of AR-S staining 
showing the effect of DM-22 and AL on h-MSCs differentiation. Magnification 20X. (B) Histogram showing 
AR-S staining quantification. Data are expressed as mean ± SD of N = 8 independent experiments. Kruskal-
Wallis +Dunn’s multiple comparison test (*p < 0.05, **p < 0.01 ***p < 0.001, ****p < 0.0001) and Mann 
Whitney test (####p < 0.0001) were used for statistical analyses.
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AL-stimulated samples across all the osteogenic targets and timepoints evaluated in our analysis. In particular the 
capacity of DM-22 to significantly stimulate COLL I expression marked a striking contrast with the effect induced 
by AL and may extend the applications of DM-22 to conditions characterized by defective synthesis of collagen.
Figure 6. DM-22 stimulates gene expression of osteogenic markers. (A–H) Box plots showing mRNA 
expression of osteogenic markers in hMSCs after D14 (A,C,E,G) or D21 (B,D,F,H) in culture in the presence 
of DM-22 or AL. Expression levels of: ALP (A-B), BSP (C-D); COLL I (E,F); COLLXV (G,H) are reported. 
Data were analyzed by GLM analysis. Data are expressed as mean ± 95% confidence interval of fold increase 
compared to CTRL cells (=1) of N = 4 independent experiments. *p < 0.05 vs control samples; °p < 0.05 DM-22 
versus AL.
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Based on these data, DM-22 is the first N-BPs to display both anabolic and anti-resorptive functions in bone 
cells in vitro. Its biological activity on h-MSCs and h-OCs resembles that of H2S-releasing drugs previously tested 
by our group and others18,20,21. In particular, in vivo studies have ascertained that H2S-donors promote bone for-
mation and prevent the bone wasting effect of estrogen deficiency in mice18, making it DM-22 a suitable candidate 
to achieve a long sought mitigation of the marked suppression of bone turnover exerted by traditional BPs.
Most BPs are characterized by poor bioavailability and very high affinity for the bone mineral matrix. Even 
tough further studies to test the in vivo bioavailability of DM-22 should be done in the near future, it is conceiv-
able that the addition of aryl-isothiocianate moiety together with the “phosphonate” head of the molecule would 
lead to a local accumulation of DM-22 at the mineral bone surface, thus facilitating the local delivery of H2S. This 
would not only avoid potential systemic cytotoxicity but would locally replenish a molecule that is lowered in the 
pathological condition of bone loss due to osteoporosis18.
In conclusion, this work described the synthesis of a new H2S-hybrid N-BPs able to induce osteogenic differ-
entiation of h-MSCs and, at the same time, retaining an anti-osteoclastogenic activity in vitro.
To the best of our knowledge, no other BPs elicit this combination of pharmacological effects in h-OCs and 
h-MSCs. The relevant features of the DM-22 is that it resulted from the winning conjugation of an anti-catabolic 
agent with a H2S-releasing moiety. The new multitasking N-BPs conjugate DM-22 may therefore pave the way to 
the development of novel therapies for bone loss providing new agents with a reduced toxicity profile.
Our work marks a significant expansion of H2S-based therapeutics, which stems from the recognition of the 
important role of H2S as a signaling molecule in several organs and tissues19,40, to the field of bone metabolism. 
This work will provide novel therapeutical opportunities in the field of bone loss therapies.
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